Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
taVNS plus ciprofol vs sufentanil plus ciprofol for painless gastrointestinal endoscopy
ChiCTR2600117962Phase 4Not yet recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ciprofol and sufentanil in None (3 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Postoperative 24-hour recovery quality. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ciprofolsufentanil
Beyond the preview
Go deeper on ChiCTR2600117962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117962.